Lung Cancer

PV QA 4 - Poster Viewing Q&A 4

TU_38_3700 - The Efficacy of Accelerated Radiation Therapy By Simultaneous Integrate Boosting Combined with Chemotherapy for Patients with Limited-Stage Small Cell Lung Cancer

Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3

The Efficacy of Accelerated Radiation Therapy By Simultaneous Integrate Boosting Combined with Chemotherapy for Patients with Limited-Stage Small Cell Lung Cancer
M. Su1, J. You2, J. CUI2, M. Song2, L. Jiang2, D. LI2, H. Yu2, R. Yu2, and A. SHI2; 1Department of Radiation Oncology, Peking University First Hospital, Beijing, China, 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China

Purpose/Objective(s): To evaluate the efficacy of accelerated twice-daily radiotherapy by simultaneous integrate boosting combined with chemotherapy for patients with limited-stage small cell lung cancer. Materials/Methods: We retrospectively analyzed a total of 33 patients with limited-stage small cell lung cancer from December 2012 through September 2017. Patients were treated with accelerated radiotherapy. The therapeutic gross tumor volume (GTV) received a dose of 54Gy delivered in 30 fractions of 1.8 Gy twice daily, and the planning target volume (PTV) was treated with 45 Gy at 1.5 Gy twice-daily in 30 fractions. Concurrent chemotherapy is etoposide plus cisplatin, consisted of 100 mg of etoposide per square meter of body-surface area on days 1, 2, and 3 and 75 mg of cisplatin per square meter of body-surface area on day 1 for 3-week cycle. Results: The median age of 33 patients involved was 55 years (range, 30 to 68) .The median follow up time was 16.7months(range, 2.8 to 31.8). The one-year and two-year PFS was 76.0% and 51.4%, the one-year and two-year OS was 81.7% and 63.5%, and the the one-year and two-year locoregional failure-free survival rate was 89.1% and 76.1%, respectively. 14 patients (42.4%) experienced grade 2 acute esophagitis, while 1 patient(3.0%)experienced grade 3 acute esophagitis. 2 patients(6.1%)developed Grade 2 pneumonitis. No patient developed Grade 3 or higher radiation-related pneumonia. 11(33.3%) and 6 patiens(18.2%) experienced grade 3 and 4 hematological toxicities, respectively. Conclusion: Accelerated twice-daily radiotherapy by simultaneous integrate boosting combined with chemotherapy, might be an effective treatment for patients with limited-stage small cell lung cancer, and adverse-event rates were acceptable. We recommend that it be further confirmed by large sample prospective study.
Author Disclosure: M. Su: None. J. You: None. M. Song: None. L. Jiang: None.

Send Email for Mengmeng Su


Assets

TU_38_3700 - The Efficacy of Accelerated Radiation Therapy By Simultaneous Integrate Boosting Combined with Chemotherapy for Patients with Limited-Stage Small Cell Lung Cancer



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for The Efficacy of Accelerated Radiation Therapy By Simultaneous Integrate Boosting Combined with Chemotherapy for Patients with Limited-Stage Small Cell Lung Cancer